At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 4 enrolled
Drug / intervention
AKCEA-ANGPTL3-LRxdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Phase 2 Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Familial Partial Lipodystrophy
In Brief
A Phase 2 clinical trial evaluating AKCEA-ANGPTL3-LRx for Familial Partial Lipodystrophy. Completed, enrolled 4 participants across 1 site.
Detailed Summary
This is a single-center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for reduction of fasting triglycerides in participants with familial partial lipodystrophy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFamilial Partial Lipodystrophy
CountriesUnited States
CollaboratorsIonis Pharmaceuticals, Inc.
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 2018
Enrollment StartJun 2018
Primary CompletionJul 2019
Study CompletionAug 2019
TodayJul 2026
First PostedMay 2, 2018
Enrollment StartJun 15, 2018
Primary CompletionJul 30, 2019
Study CompletionAug 21, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.2 years ago
Interventions
AKCEA-ANGPTL3-LRxdrug
AKCEA-ANGPTL3-LRx solution for SC injection.